Duloxetine
Product Images NDC 64725-7544

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 64725-7544). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Tya Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (64725 7544)

Label for Duloxetine DR 60mg capsules, containing 30 capsules per bottle. The label indicates the medication is prescription only, manufactured by TEVA, and repackaged by TYA Pharmaceuticals, located in Tallahassee, FL. It includes placeholders for lot number and expiration date, a barcode, and a note to see the package insert for dosing information.*

FDA Label Image

Figure 5 (Figure 5)

A line graph comparing the percentage of patients improved with Duloxetine 60 mg/120 mg once daily versus placebo across various percent improvements in pain from baseline. The x-axis shows percent improvement in pain from baseline (BOCF), and the y-axis shows the percentage of patients improved, with Duloxetine consistently showing higher improvement percentages than placebo.*

FDA Label Image

Figure 6 (various levels of pain relief measured 24 hr)

A line chart comparing placebo and Duloxetine 60 mg once daily showing the percentage of patients improved versus percent improvement in pain from baseline (BOCF). The chart's y-axis represents the percentage of patients improved, and the x-axis shows percent improvement in pain, with data points indicating higher patient improvement percentages for Duloxetine compared to placebo.*

FDA Label Image

Figure 7-patients Achieving Various Levels Of Pain Relief (Figure 7 Patients Achieving Various Levels Of Pain Relief)

A line graph illustrating the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for Duloxetine 60 mg/120 mg once daily compared to placebo. The x-axis represents percent improvement in pain, ranging from >0 to 100%, and the y-axis shows the percentage of patients improved, from 0 to 100%. Two lines, one for placebo and one for Duloxetine, are plotted, showing duloxetine generally maintaining higher patient improvement percentages across pain improvement levels.*

FDA Label Image

Structural Formula Duloxetine Hydrochloride (Image 01)

Chemical structure diagram of duloxetine hydrochloride, showing the molecular arrangement with aromatic rings, a thiophene group, and an amine hydrochloride moiety.*

FDA Label Image

Figure 1 (Image 02)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine dosed at 60 mg BID, 60 mg QD, 20 mg QD, and placebo. The graph compares the effectiveness of different Duloxetine dosages and placebo in pain improvement.*

FDA Label Image

Figure 2 (Image 03)

A line graph showing the percentage of patients improved with Duloxetine 60 mg BID, Duloxetine 60 mg QD, and placebo across different percent improvements in pain from baseline. The x-axis represents percent improvement in pain from baseline (0 to 100%), and the y-axis shows the percentage of patients improved (0 to 100%). Data points indicate higher improvements for Duloxetine groups compared to placebo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.